ReviewSeminars in cancer biology2022
Checkpoint: Inspecting the barriers in glioblastoma immunotherapies.
Review in Seminars in cancer biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 23 citations in OpenAlex.
- Biomimetic Nanocarriers for Glioblastoma Therapy: Translational Advances and Strategic Challenges.Cancers · 2026Review
- Immune checkpoint crosstalk between LAG-3 and CD39/CD73 in glioblastoma: dual-pathway regulation of metabolic exhaustion and therapeutic reversal strategies.Journal of the Egyptian National Cancer Institute · 2026Review
- Reconceptualizing glioblastoma immunotherapy: a four-pillar framework to overcome multidimensional resistance.Frontiers in medicine · 2026Review
- Advances in Cellular Immune Theranostic Approaches for Glioblastoma: Current Trends and Future Directions.Cancer innovation · 2025Review
- FN1 Immunoregulation in Glioblastoma: Insights From Neutrophil-Centric Studies.Cancer science · 2025Article
- CD47 Knock-Out Using CRISPR-Cas9 RNA Lipid Nanocarriers Results in Reduced Mesenchymal Glioblastoma Growth In Vivo.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The Mechanism of Action of Exosomes Derived from Glioblastoma Cells.Current medicinal chemistry · 2025Review
- Research advances in immune agonists and their nanoparticles for enhancing the immunotherapeutic efficacy of PD-1 inhibitors in malignancies.Frontiers in oncology · 2025Review
- Analysis of transcription profiles for the identification of master regulators as the key players in glioblastoma.Computational and structural biotechnology journal · 2024Article
- Intracellular C5aR1 inhibits ferroptosis in glioblastoma through METTL3-dependent m6A methylation of GPX4.Cell death & disease · 2024Article
- GPR65 contributes to constructing immunosuppressive microenvironment in glioma.Neurosurgical review · 2024Article
- TCAF2 drives glioma cellular migratory/invasion properties through STAT3 signaling.Molecular and cellular biochemistry · 2024Article
- Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.Journal of hematology & oncology · 2024Review
- Article
- Precision medicine advancements in glioblastoma: A systematic review.BioMedicine · 2023Review
- Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model.International journal of molecular sciences · 2022Article
- Delivering Glioblastoma a Kick-DGKα Inhibition as a Promising Therapeutic Strategy for GBM.Cancers · 2022Review
- Comprehensive Analyses of Ferroptosis-Related Alterations and Their Prognostic Significance in Glioblastoma.Frontiers in molecular biosciences · 2022Article
- Emotional distress impairs immune checkpoint blockade efficacy in recurrent high-grade glioma: Insights from tumor in situ fluid analysis.Neuro-oncology advancesArticle
- Targeting the Siglec/sialic-acid axis in glioblastoma: Glycome-mediated immune evasion and emerging therapeutic platforms.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Despite an aggressive standard of care involving radiation therapy, temozolomide-based chemotherapy, and surgical resection, glioblastoma multiforme (GBM) continues to exhibit very high recurrence and mortality rates partly due to the highly plastic and heterogenous nature of the tumor. In recent years, activation of the immune system has emerged as a promising strategy in cancer therapies. However, despite recent successes in other fields, immunotherapeutic approaches continue to encounter challenges in GBM. In this review, we first discuss immunotherapies targeting the most well-studied immune checkpoint proteins, CTLA-4 and PD-1, followed by discussions on therapies targeting immune-stimulatory molecules and secreted metabolic enzymes. Finally, we address the major challenges with immunotherapy in GBM and the potential for combination and neoadjuvant immunotherapies to tip the scales in the fight against glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.